NEW YORK (GenomeWeb) – Swiss diagnostic firm ProteoMedix today announced the second closing of a Series B financing round of CHF1 million ($1.1 million), bringing the total amount raised in the round to CHF4.2 million.

Zurich-based ProteoMedix, which spun out of the lab of Swiss Federal Institute of Technology researcher Ruedi Aebersold in 2010, raised CHF3.2 million in the first round of the Series B financing last April.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.